Document is current
Any future updates will be listed below
-
Authors
Mei, Davide Antonio
Romiti, Giulio Francesco
Bucci, Tommaso
Corica, Bernadette
Imberti, Jacopo Francesco
Bonini, Niccolò
Vitolo, Marco
Shantsila, Alena
Tse, Hung-Fat
Chao, Tze-Fan
Boriani, Giuseppe
Proietti, Marco
Lip, Gregory Y. H.
- License Information
-
More Information
Article History
Received: 13 April 2024
Accepted: 20 November 2024
First Online: 2 December 2024
Declarations
:
: Patient data were obtained after the signing of a written informed consent by each patient, following the approval of the study protocol by an Institutional Review Board/Ethic Committee. The study was first approved by the National Coordinators’ main institutions (listed in the Additional File 1: List of Investigators section) and subsequently authorized by each peripheral site, under the responsibility of the lead contact and study team (all listed in the Additional File 1: List of Investigators section), according to the specific national and local regulation. Any details regarding approval numbers for the study protocol regarding any specific site could be obtained from the corresponding authors, upon reasonable request.
: Not applicable.
: GB: reports small speaker fees from Bayer, Boehringer Ingelheim, Boston, BMS, Daiichi, Sanofi and Janssen outside the submitted work.GYHL: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-PI of the AFFIRMO project on multimorbidity in AF (grant agreement No 899871), TARGET project on digital twins for personalised management of atrial fibrillation and stroke (grant agreement No 101136244) and ARISTOTELES project on artificial intelligence for management of chronic long term conditions (grant agreement No 101080189), which are all funded by the EU’s Horizon Europe Research & Innovation programme.MP: Italian national Principal Investigator of the AFFIRMO project on multimorbidity in atrial fibrillation, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 899871.GFR: GFR reports consultancy for Boehringer Ingelheim and an educational grant from Anthos, outside the submitted work. No fees are directly received personally.The other authors do not have conflict of interests to report.
